Consumption of serum lipid‐reducing drugs in Serbia compared with Scandinavian countries: a population‐based study, 2004–2008

Sabo, Ana; Tomić, Zdenko; Stilinović, Nebojša; Milijašević, B.; Mikov, Momir; Vukmirović, Saša; Horvat, Olga

doi:10.1002/pds.2045

Cited by 10 publications

(5 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Th ese results diff er from the results of studies carried out in Serbia in the period from 2004 to 2008, aft er which it is actually the most used statin simvastatin, in a percentage higher than 50% [24]. Th e increasing use of atorvastatin relative to the simvastatin can be attributed to the higher effi ciency of this drug in cholesterol-lowering eff ect [25].…”

Section: Discussionmentioning

confidence: 89%

Pharmacoepidemiological analysis of statins dispensing patterns in pharmacy practice: Profile and side effects

Deljanin¹,

Vukovic²

2016

Hosp Pharm Int Multi J

View full text Add to dashboard Cite

SUMMARYIntroduction: Modern way of life contributes to the ever increasing incidence of atherosclerosis and associated cardiovascular disease. Accordingly, prescribing of statins, drugs used for primary and secondary prevention of cardiovascular events, gains momentum worldwide. The aim of this study was to analyze profi le of drug dispensing, side eff ects frequency and correlation with treatment duration. Subjects and methods:The study included 44 randomly selected patients who used statins. The length of the follow-up was a one month, in the outpatient pharmacy situated in the city of Belgrade, where patients fi lled out the survey. Data were statistically analyzed and presented in tables and graph enclosed. Results: PResults showed that it is more frequent use of these drugs in secondary prevention of cardiovascular events, than in primary. Likewise, there is a signifi cant diff erence in distribution between diff erent therapy duration categories and indication (χ 2 = 7.726; p = 0.021) and signifi cant diff erence in distribution between diff erent categories in weight gain (χ 2 =11.535; p=0.003). The average ages of respondents were 66.93±7.65 years, and average duration of therapy 31.68 months. Conclusion: Based on the results, it can be concluded that the use of statins is justifi ed in primary prevention up to 32 months of duration. After this period additional measures concerning its justifi cation are required. From the standpoint of pharmacovigilance, it is necessary to frequently conduct the evaluation of prescriptions and use of these drugs, in order to prevent side eff ects.

show abstract

Section: Discussionmentioning

confidence: 89%

Pharmacoepidemiological analysis of statins dispensing patterns in pharmacy practice: Profile and side effects

Deljanin¹,

Vukovic²

2016

Hosp Pharm Int Multi J

View full text Add to dashboard Cite

show abstract

“…(20) Sabo et al reported lower use of statins in Serbia compared with Scandinavian countries. (24) Roth et al reported cross-country comparisons of the proportion of the population treated with lipid-modifying agents and included data from three middle-income countries. (25) While in India, growth in statin prescriptions and a large proportion of combination lipid-modifying agent product use was reported between 2006 to 2010.…”

Section: Discussionmentioning

confidence: 99%

Trends in lipid-modifying agent use in 83 countries

Blais

Yue

Yap

et al. 2021

Preprint

View full text Add to dashboard Cite

AimsLipid-modifying agents (LMAs) are increasingly used to reduce lipid levels and prevent cardiovascular events, but the magnitude of their consumption in different world regions is unknown. We aimed to describe recent global trends in LMA consumption and to explore the relationship between country-level LMA consumption and cholesterol concentrations.Methods and resultsThis cross-sectional and ecological study used monthly pharmaceutical sales data from January 2008 to December 2018, for 83 countries from the IQVIA Multinational Integrated Data Analysis System, and total and non–high-density lipoprotein (non– HDL) cholesterol concentrations from the NCD Risk Factor Collaboration. The compound annual growth rate (CAGR) was used to assess changes in LMA consumption over time. From 2008 to 2018, the use of LMAs increased from 7,468 to 11,197 standard units per 1000 inhabitants per year (CAGR 4.13%). Statins were the most used class of LMA and their market share increased in 75% of countries between 2008 and 2018. Fibrates were the most consumed nonstatin drugs. From 2013 to 2018, consumption of low-density lipoprotein lowering therapies increased (statins 3.99%; ezetimibe 4.01%; proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors 104.47%). Limited evidence supports a clear relationship between country-level changes in LMA consumption and total and non–HDL cholesterol concentrations in 2008 versus 2018.ConclusionSince 2008, global access to LMAs, especially statins, has improved. In line with international lipid guideline recommendations, recent trends indicate growth in the use of statins, ezetimibe, and PCSK9 inhibitors. Country-level patterns of LMA use and total and non–HDL cholesterol varied considerably.

show abstract

“…Statins were the predominant lipid-modifying agent although the market share of fibrates remained strong in France (~25%), Belgium (~25%) and Germany (~10%) in 2003 [21]. Sabo et al reported lower use of statins in Serbia compared with Scandinavian countries [25]. Roth et al reported cross-country comparisons of the proportion of the population treated with lipid-modifying agents and included data from three middle-income countries [26].…”

Section: Comparison With Previous Studiesmentioning

confidence: 99%

Trends in lipid-modifying agent use in 83 countries

et al. 2021

View full text Add to dashboard Cite

Background and aims: Lipid-modifying agents (LMAs) are increasingly used to reduce lipid levels and prevent cardiovascular events but the magnitude of their consumption in different world regions is unknown. We aimed to describe recent global trends in LMA consumption and to explore the relationship between country-level LMA consumption and cholesterol concentrations. Methods: This cross-sectional and ecological study used monthly pharmaceutical sales data from January 2008 to December 2018 for 83 countries from the IQVIA Multinational Integrated Data Analysis System and total and non-high-density lipoprotein (non-HDL) cholesterol concentrations from the NCD Risk Factor Collaboration. Compound annual growth rate (CAGR) was used to assess changes in LMA consumption over time. Results: From 2008 to 2018, use of LMAs increased from 7468 to 11,197 standard units per 1000 inhabitants per year (CAGR 4.13%). An estimated 173 million people used LMAs in 2018. Statins were the most used class of LMA and their market share increased in 75% of countries between 2008 and 2018. From 2013 to 2018, consumption of low-density lipoprotein lowering therapies increased (statins 3.99%; ezetimibe 4.01%; proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors 104.47%). Limited evidence supports a clear relationship between country-level changes in LMA consumption and mean total and non-HDL cholesterol concentrations in 2008 versus 2018. Conclusions: Since 2008, global access to LMAs, especially statins, has improved. In line with international lipid guideline recommendations, recent trends indicate growth in the use of statins, ezetimibe, and PCSK9 inhibitors. Country-level patterns of LMA use and total and non-HDL cholesterol varied considerably.

show abstract

Consumption of serum lipid‐reducing drugs in Serbia compared with Scandinavian countries: a population‐based study, 2004–2008

Cited by 10 publications

References 18 publications

Pharmacoepidemiological analysis of statins dispensing patterns in pharmacy practice: Profile and side effects

Pharmacoepidemiological analysis of statins dispensing patterns in pharmacy practice: Profile and side effects

Trends in lipid-modifying agent use in 83 countries

Trends in lipid-modifying agent use in 83 countries

Contact Info

Product

Resources

About